High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study

Atlantic Health System

Status and phase: Terminated; Phase 2

Conditions: Intraventricular Hemorrhage; Randomized Clinical Trial; Brain Injury; Neurodevelopmental Outcomes; Periventricular Leukomalacia; Infant, Premature; Erythropoietin

Treatments: Drug: Erythropoietin; Drug: Saline placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00589953

R06-04-004

IND12537

Details and patient eligibility

About

The highest risk for perinatal brain injury occurs among extremely premature infants who weigh less than 1250 grams at birth. Such perinatal brain injury is currently irreversible, associated with neurodevelopmental disability, and without adequate treatment modalities. Research in recent years suggest in both animal and human studies that erythropoietin (Epo) may have significant neuroprotective effects. Given the historical safe medical profile of Epo when used for anemia of prematurity but the likely need for a greater dosage regimen for activation of neuroprotective pathways against neonatal brain injury, we therefore propose this phase II study of high-dose Epo in very low birth weight infants for the prevention and/or attenuation of prematurity-related cerebral hemorrhagic-ischemic injury.

Full description

Eligible extremely premature infants will be enrolled in this double-blind, placebo-controlled randomized trial from the neonatal intensive care unit at Morristown Memorial Hospital (Morristown, New Jersey). Subjects will be enrolled within the first 24 hours of life and randomly assigned to receive Epo or saline vehicle placebo.

Standard NICU care will be provided to all subjects. Serial exams, CBC-d, reticulocyte counts, serum Epo levels, serial HUS, and head MRI will be collected at established time points during the study period. At 18 to 22 months corrected age, subjects will undergo a neurodevelopmental evaluation assessing for cerebral palsy, Bayley Scores of Infant Development-II (BSID-II) Mental Development Index (MDI), BSID-II Psychomotor Development Index (PDI), bilateral hearing aid use, and visual impairment.

Enrollment: 22 patients

Sex: All

Ages: Under 24 hours old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 500 to 1250 grams at birth
• Less than 32 weeks gestation at birth
• Less than 24 hours of life at time of enrollment

Exclusion criteria

• Congenital anomalies (chromosomal, CNS, cardiac, GI, pulmonary)
• Seizures within first 24 hours of life
• Severe neutropenia (ANC < 500 cells/microL) within first 24 hours of life
• Polycythemia (Hct > 65%) within first 24 hours of life
• Thrombocytopenia (platelets < 50K cells/microL) within first 24 hours of life
• Hypertension (SBP > 100mmHg) without vasopressor support within first 24 hours of life

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

22 participants in 2 patient groups, including a placebo group

EPO###

Placebo Comparator group

Description:

All subjects will be identified as a such by the study identifier "EPO###" where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103).

Treatment:

Drug: Saline placebo

EPO ###

Experimental group

Description:

All subjects will be identified as a such by the study identifier "EPO###" where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103).

Treatment:

Drug: Erythropoietin